21
Views
0
CrossRef citations to date
0
Altmetric
Review

Novel cancer vaccines: an update

Pages 1787-1799 | Published online: 02 Mar 2005
 

Abstract

The intellectual property literature concerning novel cancer vaccine strategies for the period 2001 – 2003 is reviewed. More than 550 citations have been identified and the majority of the citations described herein involve the identification of potential new tumour-associated antigens and novel strategies for cancer vaccine formulations to enhance the immune response. Promising progress has been made during this period in the identification of new tumour-associated antigens, the use of cytokines, immunostimulatory oligodeoxynucleotides and heat-shock proteins as vaccine adjuvants and the refinement of dendritic cell-based immunotherapy and other vaccine formulation and immunisation strategies. In addition, encouraging results have been obtained from vaccination studies of animal tumour models and a large number of novel cancer vaccines are currently under development or in early stages of clinical evaluation. Although the availability of cancer vaccines for clinical use in patient management remains a challenge to the cancer research community, the potential of vaccination to become an important treatment option for cancer patients in the foreseeable future can be treated with cautious optimism.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.